Free Trial
→ Is President Trump Lying To You With This? (From Colonial Metals) (Ad)
NASDAQ:SHPH

Shuttle Pharmaceuticals 9/3/2024 Earnings Report

Shuttle Pharmaceuticals logo
$0.18 +0.01 (+6.47%)
Closing price 04:00 PM Eastern
Extended Trading
$0.18 0.00 (-0.55%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Shuttle Pharmaceuticals EPS Results

Actual EPS
-$0.96
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Shuttle Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shuttle Pharmaceuticals Announcement Details

Quarter
Date
9/3/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Shuttle Pharmaceuticals Earnings Headlines

Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate Update
May 16, 2025 | finanznachrichten.de
Shuttle Pharma Provides Corporate Update
May 15, 2025 | globenewswire.com
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
May 29, 2025 | Colonial Metals (Ad)
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
May 8, 2025 | globenewswire.com
Shuttle Pharmaceuticals to Present Phase 2 Trial Update at Planet MicroCap Showcase: VEGAS 2025
April 24, 2025 | nasdaq.com
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025 | globenewswire.com
See More Shuttle Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shuttle Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shuttle Pharmaceuticals and other key companies, straight to your email.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals (NASDAQ:SHPH), a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

View Shuttle Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles